Company intelligence / Profile preview

GluSense

Ownership: Private
Development stage: Preclinical

Overview

The Glyde CGM system has demonstrated promising results in preclinical animal studies. The device uses a proprietary fluorescent biosensor made from engineered live cells that can replenish themselves over time, allowing for accurate year-long continuous glucose monitoring with fewer calibrations than current technologies. Human clinical trials had not yet begun as of the latest updates.

Therapeutic areas: Endocrinology
Modalities: DeviceBiologic
Industry: Physiological Monitoring

Partnerships

JDRF T1D FundRainbow Medical innovation house

Beyond the preview

Go deeper on GluSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GluSense.

Explore the full profile